marked.bio

Company

Servier Bio-Innovation

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ivosidenib 1pembrolizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

    Recruiting Phase 3 Servier Bio-Innovation Started 2024Primary completion 2028-02 NCT06127407

    ivosidenib FDA EU

    Have documented IDH1 gene-mutated disease (from a fresh tumor biopsy or the most recent banked tumor tissue available that …

    IDH1/2 mutationLocally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

  2. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

    Active, not recruiting Phase 1/2 Servier Bio-Innovation Started 2024Primary completion 2027-08 NCT06116136

    S095029pembrolizumab FDA EU

    … Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer

    MSI-H / dMMRMSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer